Capecitabine

Ovarian Neoplasms, Pancreatic Endocrine Carcinoma, refractory peritoneal cancer + 8 more
Treatment
8 FDA approvals
20 Active Studies for Capecitabine

What is Capecitabine

CapecitabineThe Generic name of this drug
Treatment SummaryCapecitabine is a chemotherapy pill that is used to treat metastatic breast and colorectal cancers. It works by entering the tumor and being converted into an anti-metabolite called fluorouracil, which stops the growth of cancer cells by stopping the production of DNA.
Xelodais the brand name
image of different drug pills on a surface
Capecitabine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Xeloda
Capecitabine
1998
61

Approved as Treatment by the FDA

Capecitabine, otherwise known as Xeloda, is approved by the FDA for 8 uses including refractory, metastatic Colorectal carcinoma and Duke's C Colon cancer .
refractory, metastatic Colorectal carcinoma
Used to treat refractory, metastatic Colorectal carcinoma in combination with Oxaliplatin
Duke's C Colon cancer
Metastatic Colorectal Carcinoma
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Docetaxel
Colorectal Carcinoma
Used to treat refractory, metastatic Colorectal carcinoma in combination with Oxaliplatin
Colorectal Neoplasms
Colorectal Neoplasms
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Docetaxel

Effectiveness

How Capecitabine Affects PatientsCapecitabine is a medicine used to treat certain types of cancer, such as metastatic breast cancer and colon cancer. It is taken orally, and is converted by enzymes in the body into a medication called fluorouracil. This medication then breaks down in both healthy and cancerous cells into two components, 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP).
How Capecitabine works in the bodyCapecitabine is a drug that is designed to target tumor cells. It is converted into a toxic form, fluorouracil, by an enzyme that is found in larger amounts in tumors than other tissue. The toxic form then works to inhibit the formation of necessary molecules for cell division. It also causes faulty RNA production, which further interferes with cell growth.

When to interrupt dosage

The recommended measure of Capecitabine is contingent upon the diagnosed affliction, such as Pancreatic Metastatic Cancer, Malignant Neoplasms and Esophageal Cancer. The quantity of dosage can be found in the table below, depending on the mode of delivery (e.g. Tablet or Tablet, film coated - Oral).
Condition
Dosage
Administration
Colorectal Neoplasms
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Pancreatic Neoplasms
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Stomach Cancer
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Ovarian Neoplasms
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Pancreatic Endocrine Carcinoma
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
refractory peritoneal cancer
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Colorectal Carcinoma
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Metastatic Breast Cancer
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Refractory Fallopian Tube Carcinoma
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Malignant Neoplasms
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Colorectal Neoplasms
500.0 mg, , 150.0 mg, 300.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Capecitabine.
Common Capecitabine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Capecitabine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Capecitabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Capecitabine is combined with Abetimus.
Abrocitinib
Major
The metabolism of Abrocitinib can be decreased when combined with Capecitabine.
Acetohexamide
Major
The metabolism of Acetohexamide can be decreased when combined with Capecitabine.
image of a doctor in a lab doing drug, clinical research

Capecitabine Novel Uses: Which Conditions Have a Clinical Trial Featuring Capecitabine?

337 active clinical trials are investigating the potential of Capecitabine to address Duke's C Colon cancer, Pancreatic Endocrine Carcinoma and refractory Peritoneal Carcinoma.
Condition
Clinical Trials
Trial Phases
Stomach Cancer
110 Actively Recruiting
Phase 2, Phase 3, Phase 1, Not Applicable, Phase 4
Colorectal Neoplasms
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Colorectal Carcinoma
0 Actively Recruiting
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Colorectal Neoplasms
0 Actively Recruiting
Refractory Fallopian Tube Carcinoma
3 Actively Recruiting
Phase 1, Phase 2
Pancreatic Endocrine Carcinoma
10 Actively Recruiting
Phase 1, Not Applicable, Phase 2
Ovarian Neoplasms
0 Actively Recruiting
refractory peritoneal cancer
0 Actively Recruiting
Pancreatic Neoplasms
27 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3

Capecitabine Reviews: What are patients saying about Capecitabine?

5Patient Review
3/23/2019
Capecitabine for Breast Cancer that has Spread to Another Part of the Body
I had some nausea when I started taking this drug, but it went away after a few doses. This is the fourth cancer drug I've tried, and I feel better on this one than all the others. Hopefully, it will keep me alive until another cure comes along.
5Patient Review
6/26/2022
Capecitabine for Colon and Rectal Cancer that has Spread to Another Area
So far, I've only experienced mild side-effects from this treatment. These include fatigue, weight gain, nausea, heartburn, dry eye, and swelling. I'm hoping that the cancer is gone after 9 cycles of this treatment.
5Patient Review
12/27/2011
Capecitabine for Breast Cancer that has Spread to Another Part of the Body
My mother took this medication for two weeks and, unfortunately, had to be hospitalized due to severe diarrhea. I believe that this medicine ultimately caused her death.
4.7Patient Review
6/26/2015
Capecitabine for Colon and Rectal Cancer that has Spread to Another Area
I swapped to this treatment from FOLFIRI i.v. drugs, and I'm much happier with it. The main side effects are fatigue and nausea, but the fatigue is worse with the i.v. medications while the nausea seems worse with these pills (although that might just be because you have to take them for two weeks).
4.3Patient Review
1/8/2020
Capecitabine for Colon and Rectal Cancer that has Spread to Another Area
The only downside I experienced was with skin irritation on my hands and feet.
3.7Patient Review
5/12/2018
Capecitabine for Breast Cancer that has Spread to Another Part of the Body
I experienced some vomiting when I first started taking these medication, but my doctor lowered the dose and increased my anti-nausea medication. After that, I was much better.
3Patient Review
6/20/2009
Capecitabine for Lymph Node Positive Colon Cancer
2.3Patient Review
2/2/2017
Capecitabine for Breast Cancer that has Spread to Another Part of the Body
The generic from Mylan caused severe gastric pain and bloating after two days of use. Discontinued use and returned to Xeloda, which does not have this side effect. Maybe it was an allergic reaction to an inactive ingredient, but there is no way to find out for sure. As a result, I am now hesitant to try other generics.
1.3Patient Review
11/20/2015
Capecitabine for Colon and Rectal Cancer that has Spread to Another Area
My wife experienced terrible side effects from this medication. She was taking 500mg pills, twice a day. After just one week, her body started shutting down. She stopped eating and drinking and started vomiting uncontrollably for 30 minutes at a time. At the time, she was only 83 pounds and 4'11". Two months later, she passed away.
1Patient Review
1/31/2010
Capecitabine for Colon and Rectal Cancer that has Spread to Another Area
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about capecitabine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of chemotherapy is capecitabine?

"They "trick" the cell into incorporating them into the cellular machinery in place of the normal substance.

Capecitabine is a type of chemotherapy that is called an antimetabolite. Antimetabolites are similar to normal substances within the cell. They "trick" the cell into incorporating them into the cellular machinery in place of the normal substance."

Answered by AI

How does capecitabine fight cancer?

"Capecitabine can be used to treat breast, colon, or rectal cancer by slowing or stopping the growth of cancer cells."

Answered by AI

What are side effects of capecitabine?

"The following are potential side effects: stomach pain, loss of fingerprints, numbness, pain, tingling, or other unusual sensations in the palms of the hands or bottoms of the feet, pain, blistering, peeling, redness, or swelling of the palms of the hands or bottoms of the feet."

Answered by AI

What is the success rate of capecitabine?

"Overall, 89% of patients taking capecitabine were still alive after 3 years, compared to 84% of patients in the control group. After 5 years, 89% of capecitabine patients were alive, compared to 83% of control patients."

Answered by AI

Clinical Trials for Capecitabine

Image of BAMF Health in Grand Rapids, United States.

GEH300079 PET/CT for Colorectal Cancer

18+
All Sexes
Grand Rapids, MI
This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET/CT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study. The study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET/CT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET/CT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.
Phase 2 & 3
Waitlist Available
BAMF HealthGE Healthcare
Have you considered Capecitabine clinical trials? We made a collection of clinical trials featuring Capecitabine, we think they might fit your search criteria.Go to Trials
Image of Helios CR Inc./RadNet in Cerritos, United States.

[18F]FAPI-74 PET for Stomach and Esophageal Cancer

18+
All Sexes
Cerritos, CA
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \[¹⁸F\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \[¹⁸F\]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from first patient screening to last patient SOC follow up. The participants will be followed-up for safety for 24 to 72 hours after the dose of \[¹⁸F\]FAPI-74 PET/CT.
Phase 3
Recruiting
Helios CR Inc./RadNetSherly Mosessian, Ph.DSOFIE
Have you considered Capecitabine clinical trials? We made a collection of clinical trials featuring Capecitabine, we think they might fit your search criteria.Go to Trials
Image of AHN West Penn Hospital in Pittsburgh, United States.

vvDD-hIL2 for Abdominal Cancer

18 - 69
All Sexes
Pittsburgh, PA
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer. The study will involve three dose levels, with three to six patients enrolled at each level. vvDD-hIL2 is a genetically modified vaccinia virus, derived from the virus previously used for smallpox vaccination. The modification is intended to target and destroy tumors while minimizing harm to healthy tissues by stimulating the body's immune response. Participants will receive an injection of vvDD-hIL2 directly into their abdominal tumors at AHN West Penn. The study team will monitor for side effects and assess tumor response to the treatment. Active participation will last up to two months, involving seven clinic visits and approximately four lab visits at AHN West Penn Hospital. Visits will include standard of care procedures as well as study-specific tests and exams. Most visits will last one to two hours, with some extending to two to three hours. The drug administration day will require a twelve-hour visit. Effectiveness and side effects will be evaluated through blood draws, oral swabs, urinalysis and tissue biopsies. Tissue samples will be used for genomic analysis and stored for potential future research. Data collected may also be used for future research purposes. Previous human trials of vvDD-hIL2 have reported side effects such as pain, rash or inflammation at the injection site, low-grade fevers, flu-like symptoms, and fatigue. There is a rare risk of rash transmission to close contacts with skin openings, and information on limiting contact and managing rash development will be provided.
Phase 1
Recruiting
AHN West Penn HospitalPatrick Wagner, MD
Have you considered Capecitabine clinical trials? We made a collection of clinical trials featuring Capecitabine, we think they might fit your search criteria.Go to Trials